Fondaparinux free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414613

CAS#: 104993-28-4 (free base)

Description: Fondaparinux Free Base is a synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Fondaparinux is a clinically approved anticoagulant pentasaccharide for the treatment of thrombotic diseases, displays better efficacy and biosafety than other heparin-based anticoagulant drugs.

Chemical Structure

img
Fondaparinux free base
CAS# 104993-28-4 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 414613
Name: Fondaparinux free base
CAS#: 104993-28-4 (free base)
Chemical Formula: C31H53N3O49S8
Exact Mass: 1,506.95
Molecular Weight: 1,508.220
Elemental Analysis: C, 24.69; H, 3.54; N, 2.79; O, 51.98; S, 17.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 104993-28-4 (free base)   114870-03-0 (sodium),  

Synonym: Fondaparinux Free Base; HSDB7845; HSDB-7845; HSDB 7845; Org-31540; Org31540; Org 31540; SR90107; SR 90107; SR-90107

IUPAC/Chemical Name: (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-carboxylic acid

InChi Key: KANJSNBRCNMZMV-ABRZTLGGSA-N

InChi Code: InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-/m1/s1

SMILES Code: CO[C@H]1O[C@@H]([C@H]([C@@H]([C@H]1NS(=O)(O)=O)O)O[C@@H]2O[C@@H](C(O)=O)[C@H]([C@@H]([C@H]2OS(=O)(O)=O)O)O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3NS(=O)(O)=O)OS(=O)(O)=O)O[C@@H]4O[C@H](C(O)=O)[C@H]([C@@H]([C@H]4O)O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@H]5NS(=O)(O)=O)O)O)COS(=O)(O)=O)COS(=O)(O)=O)COS(=O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,508.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bauersachs RM. Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484221145010. doi: 10.1177/10742484221145010. PMID: 36594404.


2: Zhang L, Liu Y, Xu Z, Hao T, Wang PG, Zhao W, Li T. Design and Synthesis of Neutralizable Fondaparinux. JACS Au. 2022 Nov 14;2(12):2791-2799. doi: 10.1021/jacsau.2c00537. PMID: 36590263; PMCID: PMC9795572.


3: Thein KZ, Elsaim SA, Ma MQ, Rojas Hernandez CM, Elsayem A. Heparin-Induced Thrombocytopenia at the Emergency Department Due to Intermittent Heparin Flush in a Patient Undergoing Stem Cell Transplant. Cureus. 2022 Nov 22;14(11):e31798. doi: 10.7759/cureus.31798. PMID: 36569714; PMCID: PMC9780017.


4: Abrignani MG, Lombardo A, Braschi A, Renda N, Abrignani V, Lombardo RM. Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. World J Cardiol. 2022 Nov 26;14(11):576-598. doi: 10.4330/wjc.v14.i11.576. PMID: 36483763; PMCID: PMC9724000.


5: Zhao KN, Masci P, Dimeski G, Johnson L, Grant M, de Jersey J, Lavin MF. Potential Application of Recombinant Snake Prothrombin Activator Ecarin in Blood Diagnostics. Biomolecules. 2022 Nov 17;12(11):1704. doi: 10.3390/biom12111704. PMID: 36421717; PMCID: PMC9687618.


6: Ertan-Bolelli T, Bolelli K, Elçi SD, Belen-Apak FB. Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin. Cardiovasc Drugs Ther. 2022 Nov 19:1–8. doi: 10.1007/s10557-022-07406-z. Epub ahead of print. PMID: 36401727; PMCID: PMC9676724.


7: Boytsov SA, Shakhnovich RM, Tereschenko SN, Erlikh AD, Pevsner DV, Gulyan RG. Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM. Kardiologiia. 2022 Oct 30;62(10):3-15. Russian, English. doi: 10.18087/cardio.2022.10.n2238. PMID: 36384404.


8: Langer F, Gerlach HE, Schimke A, Heinken A, Hoffmann U, Noppeney T, Pittrow D, Klotsche J, Rabe E, Bauersachs R; INSIGHTS-SVT study group. Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice. Thromb Res. 2022 Dec;220:145-152. doi: 10.1016/j.thromres.2022.10.022. Epub 2022 Nov 5. PMID: 36370650.


9: Apostu D, Berechet B, Oltean-Dan D, Mester A, Petrushev B, Popa C, Gherman ML, Tigu AB, Tomuleasa CI, Barbu-Tudoran L, Benea HRC, Piciu D. Low-Molecular- Weight Heparins (LMWH) and Synthetic Factor X Inhibitors Can Impair the Osseointegration Process of a Titanium Implant in an Interventional Animal Study. Medicina (Kaunas). 2022 Nov 3;58(11):1590. doi: 10.3390/medicina58111590. PMID: 36363548; PMCID: PMC9694659.


10: Murray A, Yan L, Gibson JM, Liu J, Eliezer D, Lippens G, Zhang F, Linhardt RJ, Zhao J, Wang C. Proline-Rich Region II (PRR2) Plays an Important Role in Tau-Glycan Interaction: An NMR Study. Biomolecules. 2022 Oct 27;12(11):1573. doi: 10.3390/biom12111573. PMID: 36358923; PMCID: PMC9687896.


11: Yamashita A, Hisatake S, Kiuchi S, Kabuki T, Ikeda T. Effectiveness of Fondaparinux in the Japanese Population with Acute Venous Thromboembolism -A Study Comparing Patients with and without Cancer. Intern Med. 2022 Nov 2. doi: 10.2169/internalmedicine.0296-22. Epub ahead of print. PMID: 36328572.


12: Abo Elmaaty A, Eldehna WM, Khattab M, Kutkat O, Alnajjar R, El-Taweel AN, Al-Rashood ST, Abourehab MAS, Binjubair FA, Saleh MA, Belal A, Al-Karmalawy AA. Anticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies. Int J Mol Sci. 2022 Oct 13;23(20):12235. doi: 10.3390/ijms232012235. PMID: 36293094; PMCID: PMC9603561.


13: Nusanti S, Putera I, Sidik M, Edwar L, Koesnoe S, Rachman A, Kurniawan M, Edi Tarigan TJ, Yunus RE, Saraswati I, Zoraida Soraya SH, Pratomo TG, Nora RD. A case of aseptic bilateral cavernous sinus thrombosis following a recent inactivated SARS-CoV-2 vaccination. Taiwan J Ophthalmol. 2022 Jun 15;12(3):334-338. doi: 10.4103/tjo.tjo_25_22. PMID: 36248079; PMCID: PMC9558469.


14: Zhang G, Yang K, Wang L, Cheng Y, Liu C. Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin. Org Biomol Chem. 2022 Nov 2;20(42):8323-8330. doi: 10.1039/d2ob01221a. PMID: 36239281.


15: Muhamad N, Abu MA, Kalok AH, Shafiee MN, Shah SA, Ismail NAM. Safety and effectiveness of fondaparinux as a postpartum thromboprophylaxis during puerperium among muslim women: A single centre prospective study. Front Pharmacol. 2022 Sep 23;13:887020. doi: 10.3389/fphar.2022.887020. PMID: 36210844; PMCID: PMC9540499.


16: Santagata D, Cammà G, Donadini MP, Squizzato A, Ageno W. Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients. Expert Opin Pharmacother. 2022 Oct;23(14):1651-1665. doi: 10.1080/14656566.2022.2128757. Epub 2022 Oct 3. PMID: 36154548.


17: Sayar Z, Burke S, Mittal P, Cohen H. The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome. Lupus. 2022 Oct;31(12):1485-1490. doi: 10.1177/09612033221122147. Epub 2022 Sep 8. PMID: 36074077; PMCID: PMC9580031.


18: Wettstein L, Immenschuh P, Weil T, Conzelmann C, Almeida-Hernández Y, Hoffmann M, Kempf A, Nehlmeier I, Lotke R, Petersen M, Stenger S, Kirchhoff F, Sauter D, Pöhlmann S, Sanchez-Garcia E, Münch J. Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection. J Med Virol. 2023 Jan;95(1):e28124. doi: 10.1002/jmv.28124. Epub 2022 Sep 16. PMID: 36056630; PMCID: PMC9538173.


19: Soto Alsar J, Gutiérrez Ortiz de la Tabla A, Ortega Morán L, Muñoz Martín AJ. Treatment modalities in cancer-associated venous thromboembolism (VTE). Best Pract Res Clin Haematol. 2022 Mar;35(1):101354. doi: 10.1016/j.beha.2022.101354. Epub 2022 Jun 20. PMID: 36030074.


20: Russo V, Caputo A, Imbalzano E, Di Micco P, Frontera A, Uccello A, Orlando L, Galimberti P, Golino P, D'Andrea A. The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1095-1105. doi: 10.1080/17512433.2022.2117154. Epub 2022 Sep 6. PMID: 36017645.